Evidence map›Paper›PMID 36703975›Full record

ArticleFrontiers in immunology2022

Characterizing T cell responses to enzymatically modified beta cell neo-epitopes.

Hai Nguyen, David Arribas-Layton, I-Ting Chow, Cate Speake, William W Kwok, Martin J Hessner, Carla J Greenbaum, Eddie A James

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Breakdown and Repair of Peripheral Immune Tolerance in Type 1 Diabetes.Cold Spring Harbor perspectives in medicine · 2024
    Review
  4. Article
  5. Review
  6. Autoimmunity: the neoantigen hypothesis.Frontiers in immunology · 2024
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hai NguyenCenter for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, United States.
David Arribas-LaytonCenter for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, United States.
I-Ting ChowCenter for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, United States.
Cate SpeakeCenter for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, United States.
William W KwokCenter for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, United States.
Martin J HessnerDepartment of Pediatrics, The Medical College of Wisconsin, Milwaukee, WI, United States.
Carla J GreenbaumCenter for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, United States.
Eddie A JamesCenter for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, United States.
Virginia Mason Medical Center · USBenaroya Research InstituteMedical College of Wisconsin · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Previous studies verify the formation of enzymatically post-translationally modified (PTM) self-peptides and their preferred recognition by T cells in subjects with type 1 diabetes (T1D). However, questions remain about the relative prevalence of T cells that recognize PTM self-peptides derived from different antigens, their functional phenotypes, and whether their presence correlates with a specific disease endotype. Methods: To address this question, we identified a cohort of subjects with T1D who had diverse levels of residual beta cell function. Using previously developed HLA class II tetramer reagents, we enumerated T cells that recognize PTM GAD epitopes in the context of DRB1*04:01 or PTM IA2 epitopes in the context of DQB1*03:02 (DQ8). Results: Consistent with prior studies, we observed higher overall frequencies and a greater proportion of memory T cells in subjects with T1D than in HLA matched controls. There were significantly higher numbers of GAD specific T cells than IA2 specific T cells in subjects with T1D. T cells specific for both groups of epitopes could be expanded from the peripheral blood of subjects with established T1D and at-risk subjects. Expanded neo-epitope specific T cells primarily produced interferon gamma in both groups, but a greater proportion of T cells were interferon gamma positive in subjects with T1D, including some poly-functional cells that also produced IL-4. Based on direct surface phenotyping, neo-epitope specific T cells exhibited diverse combinations of chemokine receptors. However, the largest proportion had markers associated with a Th1-like phenotype. Notably, DQ8 restricted responses to PTM IA2 were over-represented in subjects with lower residual beta cell function. Neo-epitope specific T cells were present in at-risk subjects, and those with multiple autoantibodies have higher interferon gamma to IL-4 ratios than those with single autoantibodies, suggesting a shift in polarization during progression. Discussion: These results reinforce the relevance of PTM neo-epitopes in human disease and suggest that distinct responses to neo-antigens promote a more rapid decline in beta cell function.

Indexed as

Diabetes Mellitus, Type 1T-LymphocytesAutoantibodiesEpitopesHumansInterferon-gammaInterleukin-4PeptidesAutoantibodiesEpitopesInterferon-gammaInterleukin-4Peptidesat riskcitrullinated autoantigensdeamidated autoantigensT cellType 1 diabetes (T1D)

Identifiers

PMID36703975
PMCPMC9871889
OpenAlexW4315433700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.